CN101406675A - Medicine for treating hepatitis B - Google Patents
Medicine for treating hepatitis B Download PDFInfo
- Publication number
- CN101406675A CN101406675A CNA2008101825398A CN200810182539A CN101406675A CN 101406675 A CN101406675 A CN 101406675A CN A2008101825398 A CNA2008101825398 A CN A2008101825398A CN 200810182539 A CN200810182539 A CN 200810182539A CN 101406675 A CN101406675 A CN 101406675A
- Authority
- CN
- China
- Prior art keywords
- grams
- medicine
- radix
- hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating hepatitis B and belongs to the field of traditional Chinese medicine. The medicine consists of 20 to 50 grams of Sagina subulata, 15 to 30 grams of Raidx Astragali, 10 to 20 grams of bupleurum, 10 to 20 grams of malt, 10 to 20 grams of angelica, 10 to 20 grams of radix salviae miltiorrhizae, 10 to 20 grams of Curcuma aromatica Salisb, 10 to 20 grams of bighead atractylodes rhizome, 10 to 20 grams of Tuckahoe, 10 to 20 grams of endothelium corneum gigeriae galli, 5 to 10 grams of szechuan lovage rhizome and 5 to 10 grams of honey-fried licorice root. More than twenty years clinic application and application to thousands of patients show that the medicine can remarkably improve the physique of patients and relieve symptoms, and has outstanding anti-symptomatic and anti-HBV treatment effect. The medicine can achieve a negative conversion ratio of HBsAg of more than 20 percent and a negative conversion ratio of HBeAg of more that 70 percent.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of hepatitis B, belong to tcm field.
Background technology
Hepatitis B is the commonly encountered diseases and the frequently-occurring disease of China, and the serious threat people's health and lives safety has also been brought huge financial burden to society.Through numerous scientists in the whole world and unremitting effort medical, prevention work person, all obtaining certain achievement aspect the cause of disease, pathogeny, diagnosis and the treatment of chronic hepatitis B in recent years.Yet, since hepatitis B virus pathogenesis and human immune system's high complexity, the present specific medicament that does not also have to remove hepatitis B virus infection.
In the today that has multiple anti-hepatitis virus medicine, the hepatitis B virus drug resistance has become the challenge of current treating hepatitis B field maximum.At some cognitions of present hepatitis B patient existence and the mistaken ideas on the medication attitude, pay attention to just controlling, prevent drug resistance, will become the main direction of chronic viral hepatitis B antiviral therapy.Along with to the going deep into of hepatitis B clinical research, antiviral therapy is developed into the key of effective treatment gradually.1986, first interferon came out, and had fired " first rifle " of hepatitis B virus antiviral treatment; 1999, the nucleoside analog medicine lamivudine listing of first resistance hepatitis B virus; 2005, be used for the nucleoside analog New Drug of Adefovir Dipivoxil listing of anti-lamivudine; 2005, long-acting interferon glycol interferon (α-2a) listing; 2005, the listing of nucleoside analog new drug Entecavir; 2007, glycol interferon (α-2b) go on the market in succession with nucleoside analog new drug Sebivo.Now, the patient has had the chance of many selection anti-hepatitis virus medicines, and clinical efficacy also is significantly improved, but has a kind of saying to afford food for thought: " saw curative effect, saw drug resistance, and saw purse more than 3 years in 1 year in 1 year." although this saying is biased a bit; also show to a certain extent; in the today that has multiple medicines to select, improper if initial therapy is selected, produce viral drug resistance and cause changing dressings; drug resistance more then; change dressings again or dosing, so sequential therapy, what the chronic viral hepatitis B patient may face is multidrug resistance; walk narrowly more at the Lu Shangyue of treatment, has arrived the available stage of no medicine until at last.At that time, but the patient may spend the starting point that a lot of expenses and time got back to treatment, and than more fearful before the treatment be that the patient may not have effective medicine can select again.
Summary of the invention
The objective of the invention is deficiency at prior art, provide a kind of short treating period, rapid-action, cost is low, do not produce drug resistance, a kind of medicine for the treatment of hepatitis B that does not rebound after more.
Technical scheme of the present invention is:
A kind of medicine for the treatment of hepatitis B is made up of following compatibility of drugs
Herba Phyllanthi Urinariae 20～50g, the Radix Astragali 15～30g, Radix Bupleuri 10～20g, Fructus Hordei Germinatus 10～20g, Radix Angelicae Sinensis 10～20g, Radix Salviae Miltiorrhizae 10～20g, Radix Curcumae 10～20g, the Rhizoma Atractylodis Macrocephalae 10～20g, Poria 10～20g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Chuanxiong 5～10g, Radix Glycyrrhizae Preparata 5～10g.
Advantage of the present invention and characteristics:
Pharmaceutical research shows that the present invention can effectively suppress hepatitis B virus, can with the HBV-RNA specific bond, by reducing the level of hepatitis B virus duplication intermediate HBV-RNA, effectively suppress virus replication; The hypertrophy that can suppress hepatic stellate cell, activation and minimizing collagen protein synthesis directly influence connective tissue metabolism, thereby suppress and the reverse hepatic fibrosis; Hepatocyte injury there is significant protective effect, also can effectively resists hepatocyte injury simultaneously, primary hepatocarcinoma is had preventive effect.
The present invention be inherit on the basis for the treatment of the liver secret recipe handed down from one's ancestors widely collect current expert again, the well-known doctor parent offers efficacious medicine,divination,and similar arts, selects its elite and forms, and is precious.Through nearly 20 years clinical practice, thousands of routine patient's checkings can obviously improve patient's body constitution, relief of symptoms, are demonstrating good curative effect aspect anti-hepatic fibrosis, the anti-hepatitis virus.The negative conversion rate 20% of HBsAg is reached above, the negative conversion rate of HBeAg reaches more than 70%.
The specific embodiment
Below in conjunction with embodiment, the present invention is further described.
Most preferred embodiment of the present invention:
Herba Phyllanthi Urinariae 50g, Radix Astragali 25g, Radix Bupleuri 10g, Fructus Hordei Germinatus 10g, Radix Angelicae Sinensis 10g, Radix Salviae Miltiorrhizae 10g, Radix Curcumae 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Chuanxiong 5g, Radix Glycyrrhizae Preparata 5g.
The present invention is preparation process routinely, can be made into the multiple pharmaceutical dosage form that is applicable to clinical use, and first-selected dosage form is a decoction.
Application process: 1 dose of every day, decocting, early, take evening at twice.30 days is a course of treatment, and most of patients can be fully recovered within 1～3 course of treatment.
Claims (2)
1, a kind of medicine for the treatment of hepatitis B is characterized in that: it is by Herba Phyllanthi Urinariae 20～50g, the Radix Astragali 15～30g, Radix Bupleuri 10～20g, Fructus Hordei Germinatus 10～20g, Radix Angelicae Sinensis 10～20g, Radix Salviae Miltiorrhizae 10～20g, Radix Curcumae 10～20g, the Rhizoma Atractylodis Macrocephalae 10～20g, Poria 10～20g, Endothelium Corneum Gigeriae Galli 10～20g, Rhizoma Chuanxiong 5～10g, Radix Glycyrrhizae Preparata 5～10g makes.
2, a kind of medicine for the treatment of hepatitis B according to claim 1 is characterized in that: it is by pearl grass 50g, Radix Astragali 25g, Radix Bupleuri 10g, Fructus Hordei Germinatus 10g, Radix Angelicae Sinensis 10g, Radix Salviae Miltiorrhizae 10g, Radix Curcumae 10g, Rhizoma Atractylodis Macrocephalae 10g, Poria 10g, Endothelium Corneum Gigeriae Galli 10g, Rhizoma Chuanxiong 5g, Radix Glycyrrhizae Preparata 5g makes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101825398A CN101406675A (en) | 2008-12-08 | 2008-12-08 | Medicine for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101825398A CN101406675A (en) | 2008-12-08 | 2008-12-08 | Medicine for treating hepatitis B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101406675A true CN101406675A (en) | 2009-04-15 |
Family
ID=40570020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101825398A Pending CN101406675A (en) | 2008-12-08 | 2008-12-08 | Medicine for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101406675A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
| CN113546145A (en) * | 2020-04-23 | 2021-10-26 | 杨守信 | Pill for treating hepatitis B |
| CN115671240A (en) * | 2022-11-16 | 2023-02-03 | 四川中医肝病医院有限公司 | Liver-soothing and body-strengthening granule |
-
2008
- 2008-12-08 CN CNA2008101825398A patent/CN101406675A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214633A (en) * | 2020-03-09 | 2020-06-02 | 耿禄 | Formula for treating infectious hepatitis B |
| CN113546145A (en) * | 2020-04-23 | 2021-10-26 | 杨守信 | Pill for treating hepatitis B |
| CN115671240A (en) * | 2022-11-16 | 2023-02-03 | 四川中医肝病医院有限公司 | Liver-soothing and body-strengthening granule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100400094C (en) | Traditional Chinese medicine for treating hepatitis B and its preparing process | |
| CN101112541A (en) | Entecavir medicinal composition and uses thereof | |
| CN101406675A (en) | Medicine for treating hepatitis B | |
| CN103446554A (en) | Traditional Chinese medicine composition for treating scapulohumeral periarthritis | |
| CN1186687A (en) | Cancer preventing curing medicine series and its preparation | |
| CN103142920A (en) | Traditional Chinese medicine composition for treating hepatitis B and preparation method thereof | |
| CN1493315A (en) | Medicine for treating chronic hepatitis B | |
| CN1100642A (en) | Chinese medicine preparation for treating viral hepatitis B | |
| CN1228063C (en) | Medicine for treating liver disease | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN101926903A (en) | Chinese medicine preparation for curing facial paralysis | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN101444582B (en) | Hepatitis B oral liquid | |
| CN103285288A (en) | Medicament for treating chronic cardiac insufficiency | |
| CN102940871A (en) | Chinese medicament for treating chronic hepatitis | |
| CN102872353B (en) | Medicament for treating hypertension dizzy | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN103006877B (en) | Formula for systemic lupus erythematosus treatment drug | |
| CN100518800C (en) | Medicinal composition for treating hepatitis B | |
| CN101152542A (en) | Traditional Chinese medicine for treating cholestatic hepatitis | |
| CN110575521A (en) | Traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B-related compensatory cirrhosis and application | |
| CN104162043A (en) | Traditional Chinese medicine used for treatment of allergic nodular cutaneous vasculitis | |
| CN1102591A (en) | Three-seedling compound mixture and formula thereof | |
| CN102949658B (en) | Drug formula for treating hepatitis | |
| CN102018930A (en) | Medicine composition for treating hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Jiang Bin Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090415 |